Poor
Not Aligned
Patient Risk:
Low
Summary
The claims concern topical hydrocortisone ointment for skin conditions, but the available label provided pertains to Hydrocortisone Rectal Suspension for ulcerative colitis. Therefore, the claims do not align with the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Hydrocortisone ointment (typically 1% over-the-counter strength) treats many common rashes caused by inflammation, allergies, or irritation, like eczema, insect bites, or contact dermatitis.
Label provided describes Hydrocortisone Rectal Suspension for ulcerative colitis, not topical hydrocortisone ointment or its skin indications.
It reduces redness, itching, and swelling by mimicking cortisol to calm the immune response.
Mechanism and topical dermatologic efficacy are not described in the rectal suspension label; no topical indications are provided in the supplied label.
Apply a thin layer 1-2 times daily for up to 7 days on adults and children over 2, unless directed otherwise.
Dosing instructions pertain to rectal suspension, not topical ointment; the supplied label does not provide topical dosing guidance.
Do not use on suspected infections (bacterial like impetigo, fungal like ringworm, viral like herpes or shingles).
The label's contraindications pertain to systemic fungal infections and ileocolostomy for rectal hydrocortisone; topical infection cautions are not described in the provided label.
Do not use on acne, rosacea, or rashes near the eyes, mouth, or genitals without doctor approval—these worsen or spread with steroids.
Not supported by the supplied rectal suspension label; topical-specific restrictions are not provided.
Skip open wounds or if the rash covers large areas (over 10% of body).
No topical usage guidance is present in the supplied label.
Clean and dry the area first.
Not present in the rectal suspension label.
Rub in gently; wash hands after.
Not present in the rectal suspension label.
Use sparingly to avoid skin thinning with prolonged use.
Dermatologic adverse effects are listed for corticosteroids in the label, but the claim about topical skin thinning is not described in the provided rectal suspension label.
Stop if no improvement in 7 days or if it worsens.
Not present in the rectal suspension label.
Short-term: mild burning, dryness, or itching.
Rectal suspension label lists local pain or burning; dryness/itching are not explicitly listed as adverse reactions for the rectal product.
Long-term or overuse: skin thinning.
Adverse effects for the rectal suspension are listed; skin thinning is a dermatologic risk associated with topical steroids, but not explicitly described for this rectal label.
Long-term or overuse: stretch marks.
Not described in the rectal suspension label.
Long-term or overuse: acne.
Not described in the rectal suspension label.
Long-term or overuse: absorption issues (rare in adults, riskier for kids/infants).
Systemic absorption risks are not described for the rectal suspension label in the provided sections.
Face/diaper area increases risks.
Not described in the rectal suspension label.
If rash persists over a week.
Not described in the rectal suspension label.
If rash spreads.
Not described in the rectal suspension label.
If blisters.
Not described in the rectal suspension label.
If oozes pus.
Not described in the rectal suspension label.
If comes with fever/swelling—could signal infection or allergy needing prescription treatment like oral meds or antibiotics.
Not described in the rectal suspension label.
Not for self-diagnosis; consult pharmacist/doctor first, especially if pregnant, breastfeeding, or on other meds.
Not described in the rectal suspension label.
Consult pharmacist/doctor first, especially if pregnant, breastfeeding, or on other meds.
Not described in the rectal suspension label.
Mild: Calamine lotion, oatmeal baths, or moisturizers like petroleum jelly.
Not described in the rectal suspension label.
Itchy allergies: Antihistamines (Benadryl).
Not described in the rectal suspension label.
Dry/eczema: Ceramide creams.
Not described in the rectal suspension label.
Severe: Prescription steroids or antibiotics.
Not described in the rectal suspension label.
Contradictions
Important Omissions
No topical hydrocortisone indication or dosing guidance is provided in the label; no administration instructions for topical use; no skin-specific contraindications or monitoring for topical use.
Importance:
Moderate
No drug interaction details for hydrocortisone topical product in the provided label.
Importance:
Moderate
No use in specific populations (pediatric, pregnancy) information for topical indication is present in the label.
Importance:
Moderate
No storage/handling guidance for topical hydrocortisone provided in the label.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Misalignment involves topical claims not supported by the rectal label; no additional specific patient risk is derived from the label excerpt provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Topical hydrocortisone skin-indication claims are not supported by the provided Hydrocortisone Rectal Suspension label; misalignment between product context and claims.
Suggested Improvement
Restrict claims to the scope of the provided label (rectal suspension for ulcerative colitis). If topical claims are intended, reference the appropriate topical hydrocortisone product label and ensure indications, dosing, contraindications, and precautions are consistent with that label.